Altai Capital Pushes for Board Seats at OraSure in 2026 Proxy Fight
Event summary
- Altai Capital nominated two directors, including founder Rishi Bajaj, for OraSure’s 2026 board election.
- OraSure’s board previously rejected Bajaj but offered alternative candidates, which Altai declined.
- OraSure has refreshed its board since 2022, adding three new independent directors, including Steven K. Boyd in October 2025.
- John P. Kenny was appointed board chair in October 2025, replacing seven departing directors since 2022.
- OraSure’s 2026 annual meeting date has not yet been scheduled.
The big picture
Altai Capital’s move to nominate directors signals an escalation in activist investing within the diagnostics sector, where board composition and strategic oversight are increasingly scrutinized. OraSure’s recent board refresh suggests a proactive stance on governance, but the proxy fight could test the balance between shareholder demands and management’s growth agenda. The outcome may set a precedent for similar battles in the healthcare diagnostics space.
What we're watching
- Proxy Fight Dynamics
- Whether Altai Capital’s nominations gain traction among OraSure shareholders, given the board’s recent refresh efforts.
- Board Independence
- How the board’s recommendation in the proxy statement may influence shareholder voting behavior.
- Strategic Oversight
- The impact of potential new directors on OraSure’s growth strategy and operational oversight.
Related topics